Navigation Links
Nutra Pharma Receives Patent for Their Multiple Sclerosis Drug
Date:10/19/2011

CORAL SPRINGS, Fla., Oct. 19, 2011 /PRNewswire/ -- Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV/AIDS), Adrenomyeloneuropathy (AMN) and Pain, announced today that its wholly-owned subsidiary, ReceptoPharm, has received approval from the United States Patent and Trademark Office (USPTO) for its patent describing the composition of matter and the use of neurotoxins for the treatment of Multiple Sclerosis (MS).

"This is the third patent to be issued to our ReceptoPharm subsidiary in the last 16 months," commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "These patents are key to the continuing development of our pipeline and provide the value for eventual commercialization of the technology or out-licensing of the drugs. We currently own or license twelve patents that protect a broad range of drug and medical device technologies," he explained.

The patent (US 8,034,777), titled "Modified anticholinergic neurotoxins as modulators of the autoimmune reaction," describes a composition of matter and method of its use for the treatment of multiple sclerosis in humans. The composition is a modified anticholinergic alpha-neurotoxin.

"This patent represents a key addition to our intellectual property portfolio," commented Dr. Paul Reid, CEO of ReceptoPharm. "While the Company has been focused on our pain therapies, we continue to support our deep, clinical pipeline. We will be supporting further pre-clinical and clinical studies in an effort to move our MS therapy forward and to eventual approval," he concluded.

Multiple Sclerosis (MS) is thought to be an autoimmune disease that primarily causes central nervous system problems. In MS, the insulating fatty material surrounding the nerve fibers, also known as myelin, which functions to speed signaling from one end of the nerve cell to the other, is attacked by cells of the immune system causing problems in signal transduction. According to the Accelerated Cure Project for Multiple Sclerosis, a national nonprofit organization, 400,000 people in the US are affected by MS and another 2 million globally. Nutra Pharma's MS drug, RPI-78M, has shown efficacy in animal models (EAE) for MS and the Company is planning new animal studies to gain more insight into the levels of protection that the drugs afford. In one study conducted in August 2007, all members of an untreated animal control group developed signs of disease with different levels of paralysis/muscle weakness. A similar group in the August 2007 study treated with RPI-78M showed no disease in 90% of the animals in both acute and chronic applications of the test. Moreover, there were no toxicities reported though the animals received doses the equivalent of 280 times a human dose.

About Nutra Pharma Corp.

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin™. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The issuance of this patent by the USPTO should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.  Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


'/>"/>
SOURCE Nutra Pharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Native Remedies NutraRx Brand of Natural Products for Medical Practitioners Among First to Earn Prestigious Emerson EQP Seal
2. Maxam Nutraceutics Introduces PCA-Rx as a Natural Chelation Alternative for Autism Spectrum Disorder Treatment
3. Nutraceutical Leader Announces Internal Promotions of Key Personnel
4. Synutra to Participate in Citis Greater China Investor Conference
5. Reportlinker Adds Nutraceutical Market
6. Reportlinker Adds Global Nutraceuticals Industry
7. Nutrastar to Present at the Cowen and Company 9th Annual Consumer Conference in NYC
8. Synutra to Announce Third Quarter Fiscal 2011 Financial Results
9. Colorcon Expands Nutraficient Product Portfolio to Include High Productivity, PVA-Based Formulations for Food Supplement Coating
10. ScienceBased Health and Hoya Surgical Optics, Inc. Combine Forces to Expand Reach of Evidence-Based Nutraceuticals in Ophthalmic Market and Enhance Patient Care
11. Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25,2016 ... the near-infrared Cellvizio platform for urological and surgical ... OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal ... regulatory milestone in the US with the 12 ... and Drug Administration (FDA). This new FDA clearance ...
(Date:5/25/2016)... India , May 25, 2016 ... Animation Market by Type (3D, 2D, 4D), by Therapeutic ... Education), by End User (Medical Device Manufacturers, Hospitals/ Clinics) ... studies the global Medical Animation Market for the forecast ... to reach USD 301.3 Million by 2021 from USD ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 /PRNewswire/ ... dringenden Bedarf zur Steuerung ... N.V. (NASDAQ: QGEN ; Frankfurt Prime ... Entwicklungsvereinbarung mit Therawis Diagnostics GmbH zur Entwicklung und ... sein. Ein erstes Projekt wird die Entwicklung und ...
Breaking Medicine Technology:
(Date:5/25/2016)... San Francisco, CA (PRWEB) , ... May 26, 2016 , ... ... 1st, 2016, from 6pm to 7.30pm PST at HP in Palo Alto, CA. This ... panel discussion will be led by clinical trial experts from the pharmaceutical company Hallux, ...
(Date:5/25/2016)... ... May 25, 2016 , ... “We are ... Partner at HealthScape Advisors. “Brad brings significant experience advising healthcare provider clients throughout ... accelerates with the implementation of MACRA, we believe that continuing to add professionals ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... The Georgia ... Award of Excellence from the Atlanta Urban Design Commission. , The annual award recognizes ... city of Atlanta’s built environment, the preservation of its physical heritage and the balance ...
(Date:5/25/2016)... ... 2016 , ... Serenity Recovery, a holistic treatment center for ... the many supplemental program options offered at their rehabilitation facility, this time focusing ... Belt in the Shorin-ryu style of Karate that originated in Okinawa, Japan, and ...
(Date:5/25/2016)... ... ... to an article published May 5th on The Daily Mail, a survey pointed ... it found that more than a third cited unappealing breath a one of their top ... a failure to brush after meals, can typically be attributed to gum disease. Moreover, the ...
Breaking Medicine News(10 mins):